Keyphrases
Ipilimumab
100%
Stereotactic Body Radiotherapy
100%
Nivolumab
100%
Phase II Study
66%
Randomized Phase II Trial
66%
Single-isocenter
33%
Non-coplanar
33%
Pancreatic Cancer
33%
Biliary Tract Cancer
33%
Tocilizumab
33%
Common Terminology Criteria for Adverse Events (CTCAE)
33%
Anal Cancer
33%
Plan Optimization
33%
Setup Uncertainty
33%
Patient-reported Outcomes
33%
Acutely Ill Patients
33%
Metastatic Pancreatic Cancer
33%
Brain Metastases
33%
Multileaf Collimator
33%
Prospective Evaluation
33%
Acute Toxicity
33%
Confidence Interval
32%
Chemoradiotherapy
26%
Clinical Benefit Rate
22%
Proton
20%
Progressive Disease
16%
Partial Response
15%
Stable Disease
14%
Isocenter
14%
Patient-Reported Outcomes Measurement Information System (PROMIS)
13%
End of Therapy
13%
Adverse Events
12%
Accruals
12%
ExacTrac
9%
Stereotactic Radiosurgery
9%
Normal Brain
9%
Volumetric Modulated Arc Therapy
9%
Rotation Error
9%
Brain Tissue
9%
Clinical Benefit
8%
Follow-up Time
8%
Fluorouracil
8%
Objective Response Rate
8%
First Cycle
8%
Tumor Microenvironment
8%
Median Progression-free Survival
8%
IL-6 Blockade
8%
No Response
8%
Gemcitabine
8%
Immune Resistance
8%
Medicine and Dentistry
Nivolumab
100%
Ipilimumab
100%
Stereotactic Body Radiation Therapy
100%
Pancreas Cancer
66%
Anal Cancer
33%
Tocilizumab
33%
Brain Metastasis
33%
Isocenter
33%
Biliary Tract Cancer
33%
Multileaf Collimator
33%
Chemoradiotherapy
33%
Patient-Reported Outcome
33%
Acute Toxicity
33%
Intensity Modulated Radiation Therapy
25%
Adverse Event
22%
Progressive Disease
16%
Disease
14%
Overall Survival
13%
Interleukin 6
10%
Progression Free Survival
10%
Brain Tissue
9%
Volumetric Modulated Arc Therapy
9%
Stereotactic Radiosurgery
9%
Treatment Planning
8%
Proton Therapy
8%
Infusion
8%
Immunotherapy
8%
Immunity
8%
Symptom
8%
Gemcitabine
8%
Tumor Microenvironment
8%
Fluorouracil
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
66%
Ipilimumab
66%
Pancreas Cancer
66%
Anus Cancer
33%
Chemoradiation Therapy
33%
Tocilizumab
33%
Acute Toxicity
33%
Disease
27%
Overall Survival
13%
Adverse Event
10%
Progression Free Survival
10%
Interleukin 6
10%
Fluorouracil
8%
Immunotherapy
8%
Gemcitabine
8%
Symptom
8%
Tumor Microenvironment
8%
